Antithyroid Drug Selection by Trimester in Pregnancy
Use propylthiouracil (PTU) during the first trimester, then switch to methimazole for the second and third trimesters. This trimester-specific approach minimizes both fetal teratogenic risk from methimazole in early pregnancy and maternal hepatotoxicity risk from prolonged PTU exposure 1, 2.
First Trimester: PTU is Preferred
During the first trimester (weeks 1-13), when fetal organogenesis occurs, PTU is the drug of choice because:
- Methimazole is associated with specific congenital malformations including choanal atresia, esophageal atresia, and aplasia cutis when used during organogenesis 1, 2, 3
- Meta-analysis confirms higher odds of birth defects with MMI versus PTU (OR 1.29,95% CI 1.09-1.53) 4
- The FDA label explicitly states methimazole may be associated with rare fetal abnormalities, making PTU preferable in the first trimester 2, 5
Second and Third Trimesters: Switch to Methimazole
After completing the first trimester (≥14 weeks), clinicians should switch from PTU to methimazole because:
- PTU carries risk of severe, potentially fatal hepatotoxicity that increases with duration of exposure 1, 5
- The FDA issued warnings about PTU-associated liver failure requiring transplantation 5
- Meta-analysis shows PTU has significantly higher odds of liver injury (OR 2.40) and elevated transaminases (OR 3.96) compared to methimazole 4
- Organogenesis is complete, eliminating the teratogenic concern with methimazole 1, 2
Practical Implementation
When switching medications at the end of the first trimester:
- Timing: Make the switch at approximately 14-16 weeks gestation 1, 6
- Dose conversion: 10 mg methimazole ≈ 100-150 mg PTU 1
- Monitoring: Check thyroid function 2 weeks after switching, then every 2-4 weeks 1
- Target: Maintain free T4 at the upper limit of normal for each trimester to avoid fetal hypothyroidism 1
Important Caveats
- If a patient cannot tolerate PTU or has an adverse reaction (including hepatotoxicity), methimazole may be used even in the first trimester—untreated hyperthyroidism poses greater risks than methimazole exposure 1
- Monitor liver function every 3-4 weeks in pregnant women on PTU, and instruct patients to report symptoms of hepatotoxicity (fatigue, nausea, anorexia, jaundice) immediately 1, 5
- Some hyperthyroid pregnant women improve as pregnancy progresses and may discontinue antithyroid drugs weeks to months before delivery 2, 5
The evidence strongly supports this trimester-specific strategy rather than using either drug throughout pregnancy, as it optimizes both maternal and fetal safety by avoiding the primary risk period for each medication 1, 2, 3, 6.